Wise, Hannah C <br/><br/>
Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.  [electronic resource] 

 -  Scientific reports  12 2019 
 - 18882 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2045-2322 
<br/><br/><label>Standard No.: </label>10.1038/s41598-019-54796-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Carcinoma, Ovarian Epithelial--drug therapy<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>DNA Damage--drug effects<br/>DNA-Activated Protein Kinase--antagonists & inhibitors<br/>Doxorubicin--analogs & derivatives<br/>Drug Therapy, Combination<br/>Etoposide--pharmacology<br/>Female<br/>Humans<br/>Mice<br/>Mice, Nude<br/>Ovarian Neoplasms--drug therapy<br/>Polyethylene Glycols--pharmacology<br/>Protein Kinase Inhibitors--pharmacology<br/>Topoisomerase II Inhibitors--pharmacology<br/>Tumor Burden--drug effects<br/>Xenograft Model Antitumor Assays